AutoImmune launches nutritional supplement
International, has begun direct sales of Colloral, a product for
the nutritional support of patients with rheumatoid arthritis.
AutoImmune, through its joint venture with Deseret Laboratories International, has begun direct sales of Colloral, a product for the nutritional support of patients with rheumatoid arthritis.
Robert C. Bishop, CEO, stated: "Colloral has undergone extensive clinical testing which demonstrated its formulation of undenatured Type II collegen to be remarkably safe and of substantial benefit to a large number of patients."
All of the development work on Colloral was carried out under IND's by AutoImmune and its collaborators, who originally anticipated marketing the product as a pharmaceutical. The company transitioned the product to the nutritional supplement category by filing a Notice of New Dietary Ingredient with the FDA.
AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.
The new product can be purchased over the Internet at www.autoimmuneinc.com
